Ustekinumab
| Use attributes for filter ! | |
| Formula | C6482H10004N1712O2016S46 |
|---|---|
| Molar mass | 145648. 06 g·mol−1 |
| Other names | CNTO 1275 |
| Trade name | Stelara |
| Target | IL-12 |
| IL-23 | |
| Elimination half-life | 15–32 days (average 3 weeks) |
| Music groups | Adalimumab |
| Vedolizumab | |
| Infliximab | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951518 |
About Ustekinumab
Ustekinumab, sold under the brand name Stelara, is a human monoclonal antibody used to treat psoriasis.